{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-118539","form_type":"8-K","ticker":null,"cik":"0001538210","company_name":"NexImmune, Inc.","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.319541+00:00","generated_at":"2026-06-16T12:45:51.517926+00:00","sec_items":["3.01","8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"NexImmune receives Nasdaq extension to Oct 23, 2023; stock moves to Capital Market","bullets":["Nasdaq granted 180-day extension until Oct 23, 2023 to regain $1 minimum bid price compliance.","Effective Apr 26, 2023, NexImmune common stock listing transferred to Nasdaq Capital Market.","Company may consider reverse stock split to regain compliance; risk of delisting remains.","Original non-compliance notice received Oct 25, 2022; grace period expired Apr 24, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-118539","json":"https://secwatch.observer/filing/0001193125-23-118539.json","markdown":"https://secwatch.observer/filing/0001193125-23-118539.md","text":"https://secwatch.observer/filing/0001193125-23-118539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523118539/0001193125-23-118539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523118539/d493965d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:45:51.517926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"769c22c532476f73b8eff38ece5305ec0f7a749f","claim":"NexImmune, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"April 26, 2023, the listing of the Company’s Common Stock will be transferred to The Nasdaq Capital Market. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will provide notice that the Company’s Common Stock will be subject to delisting. The Company would th","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1538210/000119312523118539/0001193125-23-118539-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}